Clinical Trial Update: A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study (DUET-3) evaluating XmAb23104 in patients with selected advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma
• Nasopharyngeal Carcinoma
• Pancreatic Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• XmAb23104 (XmAb23104)

Snippet

Sponsor: Xencor, Inc. | Conditions: Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma | Phase 1 | Status: COMPLETED